CIM
NVO

Confluence Investment Management’s Novo Nordisk NVO Stock Holding History

Confluence Investment Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Buy
17,385
+1,699
+11% +$73K 0.01% 233
2026
Q1 		$576K Buy
15,686
+2,643
+20% +$125K 0.01% 246
2025
Q4 		$664K Buy
13,043
+1,219
+10% +$62.3K 0.01% 248
2025
Q3 		$656K Buy
11,824
+448
+4% +$26.2K 0.01% 243
2025
Q2 		$785K Buy
11,376
+911
+9% +$62K 0.01% 226
2025
Q1 		$727K Buy
10,465
+191
+2% +$15.8K 0.01% 231
2024
Q4 		$884K Buy
10,274
+220
+2% +$23.8K 0.01% 209
2024
Q3 		$1.2M Sell
10,054
-1,210
-11% -$161K 0.02% 193
2024
Q2 		$1.61M Buy
11,264
+420
+4% +$55.7K 0.02% 187
2024
Q1 		$1.39M Sell
10,844
-72
-0.7% -$8.57K 0.02% 185
2023
Q4 		$1.13M Sell
10,916
-714
-6% -$70.6K 0.02% 191
2023
Q3 		$1.06M Sell
11,630
-3,764
-24% -$332K 0.02% 184
2023
Q2 		$1.25M Sell
15,394
-1,900
-11% -$155K 0.02% 178
2023
Q1 		$1.38M Buy
17,294
+88
+0.5% +$6.24K 0.02% 176
2022
Q4 		$1.16M Sell
17,206
-336
-2% -$19.7K 0.02% 190
2022
Q3 		$874K Sell
17,542
-1,568
-8% -$84K 0.01% 201
2022
Q2 		$1.06M Sell
19,110
-8,354
-30% -$464K 0.02% 195
2022
Q1 		$1.52M Sell
27,464
-3,818
-12% -$196K 0.02% 184
2021
Q4 		$1.75M Sell
31,282
-2,182
-7% -$118K 0.02% 187
2021
Q3 		$1.61M Buy
33,464
+368
+1% +$17.8K 0.02% 188
2021
Q2 		$1.39M Buy
33,096
+428
+1% +$16.6K 0.02% 191
2021
Q1 		$1.1M Buy
32,668
+2,118
+7% +$75.4K 0.02% 196
2020
Q4 		$1.07M Sell
30,550
-11,800
-28% -$408K 0.02% 205
2020
Q3 		$1.47M Sell
42,350
-1,792
-4% -$59.7K 0.02% 186
2020
Q2 		$1.45M Sell
44,142
-46
-0.1% -$1.47K 0.02% 187
2020
Q1 		$1.33M Buy
+44,188
New +$1.32M 0.03% 190

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Confluence Investment Management's NVO Position: Q2 2026 in Review

Confluence Investment Management increased its Novo Nordisk (NVO) stake by 11% in Q2 2026, buying an estimated $73K and bringing the position to 17,385 shares worth $833K. The position accounts for 0.01% of the portfolio, ranked #233.

Confluence Investment Management first reported a position in NVO in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.75M in Q4 2021. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Confluence Investment Management held 17,385 shares of Novo Nordisk worth $833K as of Q2 2026.
  • Confluence Investment Management bought 1,699 Novo Nordisk shares in Q2 2026, an estimated $73K.
  • Novo Nordisk made up 0.01% of Confluence Investment Management's portfolio in Q2 2026, its #233 holding.
  • Confluence Investment Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 26 quarters since.
  • Confluence Investment Management's Novo Nordisk position peaked at $1.75M in Q4 2021.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Confluence Investment Management's 13F filing for Q2 2026, filed 1 Jul 2026.